CN1061537C - Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases - Google Patents
Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases Download PDFInfo
- Publication number
- CN1061537C CN1061537C CN97103970A CN97103970A CN1061537C CN 1061537 C CN1061537 C CN 1061537C CN 97103970 A CN97103970 A CN 97103970A CN 97103970 A CN97103970 A CN 97103970A CN 1061537 C CN1061537 C CN 1061537C
- Authority
- CN
- China
- Prior art keywords
- monascus
- monas cuspurpureus
- cuspurpureus went
- sato
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to monascus which is newly cultivated. The monascus belongs to a traditional Chinese medicine which not only can reduce blood fat but also can reduce cholesterol content; the monascus has the functions of strengthening the spleen, reinforcing the stomach, activating blood circulation and dissipating blood stasis, and the side effect is little. The monascus of the present invention can be used for treating hyperlipidemia and relevant cardiovascular and cerebrovascular diseases.
Description
What the present invention relates to is a kind of Chinese medicine monascus preparation, and said preparation has treatment hyperlipidemia and cardiovascular and cerebrovascular diseases associated effect; The invention still further relates to preparation and have the method for the Monas cuspurpureus Went of described medical function, belong to field of medicaments.
Monas cuspurpureus Went is a kind of Chinese medicine commonly used, and its use is in the history in existing more than 1,000 year of China.It is documented that the invention of Monas cuspurpureus Went just has the record of " Monas cuspurpureus Went is cooked meat " about the Tang Dynasty among the five generation people Tao Guzai " clear different record " of Tang Yihou.In the Compendium of Material Medica of the Ming Dynasty, Li Shizhen (1518-1593 A.D.) has been done the most complete argumentation to Monas cuspurpureus Went, uses till today always.Until the modern times, Monas cuspurpureus Went still uses as food therapy agent among the people, is again a kind of common food additive, is widely used among the food such as food, beverage.Monas cuspurpureus Went also has the spleen invigorating stomach strengthening as Chinese medicine, and the effect of blood circulation promoting and blood stasis dispelling in " Beijing's Chinese crude drug concocted specification " book, is listed in the local medical material in Beijing.But, by the Monas cuspurpureus Went of at present general production method preparation and since use stress the purpose difference, the effect of its blood fat reducing is very little, loses its medical value gradually, also never as the drug use of treatment hyperlipidemia.At present, the useful Lovastain of medicine, the suffering of treatment hyperlipidemia are cut down the Western medicine of preparations such as its fourth, though curative effect is better, side effect are arranged.In addition, this class medicine is that the effect of triglyceride reducing is not ideal enough based on T-CHOL in the reduction human body.
The present invention seeks at a kind of not only blood fat reducing of above-mentioned Chinese medicine and Western medicine shortcoming development separately but also Chinese medicine that can cholesterol reducing.
The object of the invention also is to provide a kind of and has spleen invigorating stomach strengthening, function of promoting blood circulation to disperse blood clots and the extremely low medicine of side effect, and this medicine can be used for treating hyperlipidemia and cardiovascular and cerebrovascular diseases associated.
The object of the invention also is to provide a kind of preparation technology of Monas cuspurpureus Went, and the Monas cuspurpureus Went of this prepared has the effect of blood fat reducing, cholesterol reducing.
The technical scheme that realizes the object of the invention is as follows.
At first, prepare Monas cuspurpureus Went of the present invention, preparation technology is:
1, preparation culture medium:
Be made up of beerwort or murphy juice, sugar and zymic mixture and water, wherein beerwort or murphy juice account for 2%, and sugar accounts for 2-6%, and yeast accounts for 0.5%, and all the other are water.
Culture medium used in the present invention also can be conventional ordinary culture medium, comprises carbon source, nitrogenous source and phosphorus source and other inorganic salt etc. on a small quantity.
Carbon is former to be comprised as grains such as rice, Semen setariae, saccharide, some organic compound such as glycerol etc.
Former various beans, peptone, yeast powder, Carnis Bovis seu Bubali cream and the inorganic salt containing nitrogen of comprising of nitrogen.
Other inorganic salt such as MgSO
4, FeCL
3Deng;
2, in per 100 gram Semen oryzae sativaes, add 40-80 milliliter culture fluid, the control pH value is between 2.5-8.0, and high temperature (121 ℃) is sterilized;
3, inoculation monascus ruber strain:
The inventor has filtered out monascus ruber strain specially through secular experimentation, and the Monas cuspurpureus Went that makes promptly has the effect that blood fat reducing again can cholesterol reducing, and can the spleen invigorating stomach strengthening, blood circulation promoting and blood stasis dispelling and side effect is extremely low.This also is the place of key problem in technology of the present invention.
The monascus ruber strain that can realize the object of the invention is:
Mauve aspergillar (Monascus purpureus), this bacterial strain carries out preservation at China Microbial Culture Preservation Commission common micro-organisms center, and preserving number is CGMCC NO.0272.
Following known monascus ruber (referring to " Chinese strain catalogue ", 1992, China Microbial Culture Preservation Commission writes, China Machine Press) also can realize the object of the invention:
(1), the Monascus anka Nakazawa et sato (Monascus albidus) that turns white
AS?3．570
AS?3．4440
(2), Monascus rubber van Tieghem (Monascus fuliginosus sato)
AS 3．569
IFFI?05035
(3), feathering Monascus anka Nakazawa et sato (Monascus pilosus Sato)
AS?3．4444
AS?3．4633
AS?3．4646
AS?3．4647
(4), fur Monascus anka Nakazawa et sato (Monascus pubigerus Sato)
AS?3．4445
AS?3．4634
(5), Bath Monascus anka Nakazawa et sato (Monascus paxii)
AS?3．4453
(6), red mould aspergillosis (Monascus ruber van Tieghem)
AS?3．549
4, cultivate more than 4 days at 7-35 ℃ of bottom fermentation, preferred cultivation temperature is 15-35 ℃, and preferred incubation time is more than 9 days;
5, with culture high temperature (121 ℃) sterilization, oven dry is pulverized, and is standby.
Monas cuspurpureus Went for above-mentioned preparation can be used the 70-95% ethanol extraction, and evaporation and concentration is standby to doing.
The Monas cuspurpureus Went of above-mentioned preparation or its crude extract, can be prepared into various preparations, for example according to the pharmaceutical preparation of routine, capsule, tablet, pill, powder and liquid preparation etc. are used for fields such as medicine, health care medicine, health food and food additive.In being prepared into the process of preparation, can add conventional excipient.
The Monas cuspurpureus Went of the present invention's preparation contains Lovastain (Lovastatin) and derivant thereof (comprising issuable Dewaterring Lovastain dchydratedlovastatin in the Monas cuspurpureus Went course of processing), for example:
Hydroxy acid formula Lovastain lactone formula Lovastain Dewaterring Lovastain
Hydroxy-acid lactone dehydrated
lovastatin lovastatin lovastatin
What the present invention emphasized is a class monascus ruber bacterial strain that refers in particular to above-mentioned, the Monas cuspurpureus Went that comes out by fermenting process of preparing, the drug effect that had both had traditional Monas cuspurpureus Went, improve greatly again wherein Lovastain and the content of related substances, overcome both original deficiencies separately, strengthened their comprehensive medical effects.Medicine of the present invention has the effect of remarkable cholesterol reducing, triglyceride reducing, high density lipoprotein increasing and reduction atherogenic index.Western medicine Lovastain class medicine is to reduce T-CHOL in the human body, and the effect of triglyceride reducing is not ideal enough.The Monas cuspurpureus Went of the present invention's preparation not only has the effect of cholesterol reducing, and has strengthened the effect of triglyceride reducing, and medicine of the present invention is much smaller than the side effect of Western medicine Lovastain.Medicine of the present invention can be used for treating hyperlipemia card and relative other cardiovascular and cerebrovascular disease, as atherosclerosis, coronary heart disease, myocardial infarction, diabetes, hypertension, thrombotic disease, cerebral infarction etc.All these effects are that independent traditional Monas cuspurpureus Went or Western medicine Lovastain is inaccessible.
According to China Medical Sciences Academy Fu Wai Hospital, Beijing Hospital, Dongzhimen Hospital, Beijing Univ of Traditional Chinese Medicine, the clinical trial in Harbin Medical University clinical pharmacology base proves, medicine of the present invention has comprehensive therapeutic effect aspect cholesterol reducing: the effective percentage that reduces serum total cholesterol (TC) is 23.0%, the effective percentage that reduces serum levels of triglyceride (TG) is 36.5%, the effective percentage that reduces low density lipoprotein, LDL (LDL-C) is 28.5%, the effective percentage that reduces atherogenic index is 34.2%, the effective percentage of high density lipoprotein increasing cholesterol (HDL-C) is 19.6%, total effective rate 93.2%.Total obvious effective rate 79.7%.Take can alleviate or eliminate uncomfortable in chest, chest pain in medicine 15-20 of the present invention days, breathe hard, symptom such as dizziness, numb limbs and tense tendons.Safe, do not see toxic and side effects.
Embodiment 1
1), preparation culture medium:
Beerwort or murphy juice 2%, sugar 4%, yeast 0.5%, all the other are water;
2), in per 100 gram Semen oryzae sativaes, adds 40 milliliters of culture fluid, the control pH value is 3.0, and high temperature (121 ℃) is sterilized;
3), the inoculation monascus ruber strain Mauve aspergillar (Monascus purpureus), preserving number is CGMCC NO.0272;
4) cultivated 4 days at 30 ℃ of bottom fermentations;
5), with culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 2 preparations medicine capsule of the present invention
The preparation culture medium is as follows:
Beerwort or murphy juice 2%, sugar 4%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes or the Semen setariae, add 80 milliliters of culture fluid, the control pH value is 6.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain Monascus anka Nakazawa et sato (Monascusalbidus) AS 3.570 that turns white; Cultivated 10 days at 25 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention; Ratio with 1: 2 in Monas cuspurpureus Went adds excipient sucrose, and is encapsulated, promptly gets medicine of the present invention.
Embodiment 3
The preparation culture medium:
Beerwort 2%, sugar 4%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 50 milliliters of culture fluid, the control pH value is 4.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain Monascus anka Nakazawa et sato (Monascus albidus) AS 3.4440 that turns white; Cultivated 9 days at 20 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 4
The preparation culture medium:
Murphy juice 2%, sugar 4%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 60 milliliters of above-mentioned culture fluid, the control pH value is 5.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain Monascus rubber van Tieghem (Monascusfuliginosus Sato) AS 3.569; Cultivated 12 days at 25 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 5
The preparation culture medium:
Beerwort 2%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 80 milliliters of above-mentioned culture fluid, the control pH value is 6.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain Monascus rubber van Tieghem (Monascusfuliginosus Sato) IFFI 05035; Cultivated 12 days at 25 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 6
The preparation culture medium:
Corn juice or murphy juice 2%, sugar 4%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 80 milliliters of above-mentioned culture fluid, the control pH value is 6.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain feathering Monascus anka Nakazawa et sato (Monascus pilosusSato) AS 3.4444; Cultivated 11 days at 30 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 7
The preparation culture medium:
Murphy juice 3%, sugar 5%, yeast 0.8%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 60 milliliters of above-mentioned culture fluid, the control pH value is 5.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain fur Monascus anka Nakazawa et sato (Monascuspubigerus Sato) AS 3.4445; Cultivated 9 days at 25 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 8
The preparation culture medium:
Murphy juice 3%, sugar 5%, yeast 0.8%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 60 milliliters of above-mentioned culture fluid, the control pH value is 7.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain Bath Monascus anka Nakazawa et sato (Monascuspaxii) AS 3.4453; Cultivated 15 days at 24 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 9
The preparation culture medium:
Murphy juice 4%, sugar 3%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 50 milliliters of above-mentioned culture fluid, the control pH value is 7.0, and high temperature (121 ℃) is sterilized; Red mould aspergillosis (the Monascus rubervan Tieghem) AS 3.549 of inoculation monascus ruber strain; Cultivated 9 days at 35 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention.
Embodiment 10 preparations medicinal tablet of the present invention
The preparation culture medium is as follows:
Beerwort or murphy juice 2%, sugar 4%, yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add 80 milliliters of culture fluid, the control pH value is 6.0, and high temperature (121 ℃) is sterilized; Inoculation monascus ruber strain Monascus anka Nakazawa et sato (Monascusalbidus) AS 3.570 that turns white; Cultivated 10 days at 25 ℃ of bottom fermentations; With culture high temperature (60-121 ℃) sterilization, oven dry is pulverized, and crosses 100 mesh sieves, makes Monas cuspurpureus Went of the present invention; Ratio with 1: 5 in Monas cuspurpureus Went adds excipient starch, and pelletize adds magnesium stearate, and tabletting promptly gets medicine of the present invention.
Claims (6)
1, prevention or treatment hyperlipemia and cardiovascular and cerebrovascular diseases associated Monas cuspurpureus Went pharmaceutical preparation is characterized in that said preparation contains the Monas cuspurpureus Went with following method preparation of treatment effective dose, and said preparation method is:
Prepare conventional culture fluid; In per 100 gram Semen oryzae sativaes, add 40-80 milliliter culture fluid, control pH value between 2.5-8.0,121 ℃ of high temperature sterilizes; Inoculation monascus ruber strain; Cultivate more than 4 days at 7-35 ℃ of bottom fermentation; Culture is sterilized under 60-121 ℃ of temperature, and oven dry is pulverized, and with the Monas cuspurpureus Went that is prepared from 70-95% ethanol extraction, evaporation and concentration is made various pharmaceutical preparatioies to doing.
2, Monas cuspurpureus Went pharmaceutical preparation according to claim 1 is characterized in that said monascus ruber strain is to be selected from any in the following monascus ruber:
Mauve aspergillar, preserving number are CGMCC No.0272;
Monascus anka Nakazawa et sato turns white
AS?3．570
AS?3．4440；
Monascus rubber van Tieghem
AS 3．569
IFFI 05035；
The feathering Monascus anka Nakazawa et sato
AS?3．4444
AS?3．4633
AS?3．4646
AS?3．4647；
The fur Monascus anka Nakazawa et sato
AS?3．4445
AS?3．4634；
The Bath Monascus anka Nakazawa et sato
AS?3．4453
Red mould aspergillosis
AS?3．549。
3, Monas cuspurpureus Went pharmaceutical preparation according to claim 1 is characterized in that described cultivation temperature is 15-35 ℃, and incubation time is more than 9 days.
4, Monas cuspurpureus Went pharmaceutical preparation according to claim 1 is characterized in that the central carbon source of described Monas cuspurpureus Went bacterium culture medium is selected from grain, saccharide, organic compound; Nitrogenous source is selected from beans, peptone, yeast powder, Carnis Bovis seu Bubali cream and inorganic salt containing nitrogen.
5, a kind of preparation method with Monas cuspurpureus Went of blood fat reducing, cholesterol reducing effect, it is characterized in that any by following method fermenting process of preparing with in the following monascus ruber strain: Mauve aspergillar, preserving number are CGMCC No.0272;
Monascus anka Nakazawa et sato turns white
AS?3．570
AS?3．4440；
Monascus rubber van Tieghem
AS 3．569
IFFI 05035；
The feathering Monascus anka Nakazawa et sato
AS?3．4444
AS?3．4633
AS?3．4646
AS?3．4647；
The fur Monascus anka Nakazawa et sato
AS?3．4445
AS?3．4634；
The Bath Monascus anka Nakazawa et sato
AS?3．4453
Red mould aspergillosis
AS?3．549；
The preparation culture medium:
Beerwort or fermented bean drink 2%, the mixture of sugar 4% and yeast 0.5%, all the other are water;
In per 100 gram Semen oryzae sativaes, add the above-mentioned culture fluid of 40-80 milliliter, control pH value between 2.5-8.0,121 ℃ of high temperature sterilizes; Inoculation monascus ruber strain; Cultivate more than 4 days at 7-35 ℃ of bottom fermentation; Culture is sterilized under 60-121 ℃ of temperature, and oven dry is pulverized.
6, a kind of monascus ruber bacterial strain Mauve aspergillar, it is characterized in that this bacterial strain can turn out have blood fat reducing, the Monas cuspurpureus Went of cholesterol reducing effect, its preserving number is CGMCC NO.0272.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97103970A CN1061537C (en) | 1996-09-26 | 1997-04-09 | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96119835A CN1155421A (en) | 1996-09-26 | 1996-09-26 | Preparation of rice fermented with red yeast for curing hyperlipemia and cardio-cerebral diseases concerned |
| CN96119835.4 | 1996-09-26 | ||
| CN97103970A CN1061537C (en) | 1996-09-26 | 1997-04-09 | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1174037A CN1174037A (en) | 1998-02-25 |
| CN1061537C true CN1061537C (en) | 2001-02-07 |
Family
ID=25744046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97103970A Expired - Lifetime CN1061537C (en) | 1996-09-26 | 1997-04-09 | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1061537C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101113146B (en) * | 2006-07-27 | 2010-05-12 | 北京北大维信生物科技有限公司 | Process for the separation of blood fat recovery purpose-made monascus active ingredient |
| CN102743417A (en) * | 2012-05-17 | 2012-10-24 | 广东医学院 | Application of red yeast rice extract in preparation of health-care food and medicine used for controlling breast cancer |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100384981C (en) * | 2002-12-30 | 2008-04-30 | 食品工业发展研究所 | Red rice mould mutant strain and its use in preparing fermented product with blood pressure reducing activity |
| CN1329044C (en) * | 2005-03-16 | 2007-08-01 | 云南大学 | Anti-tumor active matter and its preparing method and use |
| CN100431529C (en) * | 2005-12-22 | 2008-11-12 | 王幺光 | Soft capsule for reducing blood fat and its preparing method |
| CN101757470B (en) * | 2008-12-25 | 2012-08-08 | 中国科学院成都生物研究所 | Blood fat lowering composition |
| CN103549431B (en) * | 2013-11-08 | 2015-10-07 | 张秀芬 | A kind of have health products regulating blood pressure blood fat function and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1054190A (en) * | 1991-04-01 | 1991-09-04 | 沈阳协合生物制剂技术有限公司 | From metabolic product of staphylococcus aureus, extract the method for treatment malignant tumor medication |
| CN1062761A (en) * | 1990-12-25 | 1992-07-15 | 肖英杰 | With the fecula is the method that raw material is produced red colouring agent for food, also used as a Chinese medicine |
| CN1075875A (en) * | 1993-01-01 | 1993-09-08 | 北京大学 | Antilipemic monascus and preparation method |
| CN1087523A (en) * | 1992-11-30 | 1994-06-08 | 中国人民解放军第二○三医院 | The preparation method of lichen bacillus cereus ecological preparation |
-
1997
- 1997-04-09 CN CN97103970A patent/CN1061537C/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062761A (en) * | 1990-12-25 | 1992-07-15 | 肖英杰 | With the fecula is the method that raw material is produced red colouring agent for food, also used as a Chinese medicine |
| CN1054190A (en) * | 1991-04-01 | 1991-09-04 | 沈阳协合生物制剂技术有限公司 | From metabolic product of staphylococcus aureus, extract the method for treatment malignant tumor medication |
| CN1087523A (en) * | 1992-11-30 | 1994-06-08 | 中国人民解放军第二○三医院 | The preparation method of lichen bacillus cereus ecological preparation |
| CN1075875A (en) * | 1993-01-01 | 1993-09-08 | 北京大学 | Antilipemic monascus and preparation method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101113146B (en) * | 2006-07-27 | 2010-05-12 | 北京北大维信生物科技有限公司 | Process for the separation of blood fat recovery purpose-made monascus active ingredient |
| CN102743417A (en) * | 2012-05-17 | 2012-10-24 | 广东医学院 | Application of red yeast rice extract in preparation of health-care food and medicine used for controlling breast cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1174037A (en) | 1998-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1831107A (en) | Traditional Chinese medicine solid type mixed culture fermentation tech. and its application | |
| CN1273839A (en) | Transfer and modification of intestinalprobiotics fermentation culture medium to natural medicine | |
| CN110200151A (en) | A kind of yak feed addictive and preparation method thereof that yak survival rate can be improved | |
| CN1916028A (en) | Polysaccharide outside cyst of lactobacillus casei and crude product, prepartion method and application | |
| CN1065432C (en) | Antilipemic monascus and its preparation | |
| CN1061537C (en) | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases | |
| CN109452634B (en) | Fungus symbiotic fermentation blood sugar-reducing moringa oleifera and preparation method thereof | |
| CN1177636A (en) | Bacterial stain of bacillus subtilis and application thereof | |
| CN1308431C (en) | Buck-wheat flavone vinega soft capsule and preparing method | |
| CN104522750A (en) | Alga healthcare food | |
| CN105685620A (en) | Moringa oleifera oral liquid and preparation method thereof | |
| CN1320101C (en) | Aweto cytosol preparing process | |
| CN1290441C (en) | Rye-red yeast vinegar soft capsule and its preparing method | |
| CN107212392A (en) | A kind of full nutrition fermentation health-preserving food and preparation method thereof | |
| CN1275545C (en) | Eatable ants and its preparation method | |
| CN1155421A (en) | Preparation of rice fermented with red yeast for curing hyperlipemia and cardio-cerebral diseases concerned | |
| CN1215754A (en) | Method for preparing fermentation product of cordyceps, and use thereof | |
| CN1772007A (en) | Fermented aweto hypha tablet | |
| CN1296059C (en) | Mackefulan immune liquid | |
| CN107536061A (en) | Compound probiotic dietary fiber with and preparation method thereof | |
| CN109432349B (en) | Fungus symbiotic fermentation anti-tumor turmeric and preparation method thereof | |
| CN1177637A (en) | Preparation of living bacillus subtilis and preparation method thereof | |
| CN1327047A (en) | Method for cultivating variotin pecilocin with silkworm and medicinal use | |
| CN1207055C (en) | Preparation method of cordyceps biological activity multivitamin intensifying agent | |
| CN1626235A (en) | Compound preparation of forest frog, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20020508 Pledge (preservation): Preservation |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20021108 Pledge (preservation): Preservation |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20031110 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Effective date of registration: 20040510 Pledge (preservation): Preservation |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING WBL PEKING UNIVERSITY BIOTECH CO., LTD. Free format text: FORMER OWNER: ZHANG MAOLIANG Effective date: 20041112 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20041112 Address after: 100080 Great Wall Building, room 30, Haidian South Road, 619, Beijing, Haidian District Patentee after: Beijing Peking University WBL Biotech Co., Ltd. Address before: 100871 Beijing Haidian District City 314 floor, No. 206 Yan Bei yuan Peking University Patentee before: Zhang Maoliang |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20010207 |